Please login to the form below

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta. ... This includes cell and gene therapies such as Novartis’ late-stage candidate Zolgensma, which the company has

Latest news

NICE partially clears Darzalex combo in blood cancer

When used in combination with Velcade and corticosteroid medication dexamethasone, those taking Darzalex achieved an extended progression free survival of 18 months compared to existing therapies. ... Myeloma is an increasingly dynamic and competitive
CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts. New proposals in the US would lay out a route for approved CAR-T therapies to be covered by the federal Medicare ... will collect data on patients and compare the outcomes to the results seen in
How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Like many other cell and gene therapies, it could represent a cure for the disease – but comes with a huge upfront cost that healthcare systems aren’t currently set up to ... It is now working closely with NHS England (which negotiates directly on
EMA sees approval numbers rise in 2018

From these, 21 were orphan medicines (exactly 50%) and three were advanced therapy medicinal products – Novartis’ Kymriah and Gilead/Kite’s Yescarta CAR-T therapies, plus Spark’s Luxturna, co-marketed
BMS and Celgene announce $74bn merger

Two of Celgene’s most promising candidates are in BCMA-targeting CAR-T therapies for multiple myeloma – one with Bluebird, bb2121, and another with Juno, JCAR017.

More from news
Approximately 1 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Cell and gene therapy

Manufacturing of CAR-T cell therapies is a highly sophisticated, circular process that is individualised for each patient, beginning with the patient’s cells and ending with infusion in that same ... But, obviously, these prices will have to decrease
2019: CRISPR and therapeutic gene editing comes of age

TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... and that therapies based on the approach must be
Cutting through the noise: CRISPR

Scientists can then examine the effect of this change, uncovering potential disease targets for therapies. ... It’s very difficult to systemically deliver a CRISPR therapeutic selectively to the right place, especially when there are easier ways of
Drug launches to watch in 2019

1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... oral therapies such as Tyk inhibitors from Bristol-Myers Squibb
China’s clinical trial shake-up

Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Highlights in haematologic malignancy from ASH 2018

However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
Download our infographic: Addressing the biggest challenges for rare disease communities

Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
Training the next generation of biotech leaders

In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the
Addressing the biggest challenges for rare disease communities

year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
Ashfield

Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies. ... Whether we’re buying something as simple as a toaster or as expensive as a new car, we’ve all come to expect fantastic service at